Altogether, these results demonstrated that VVL-TD-IL-27 is a potential cancer immunotherapy agent that can achieve a complete response in all tumors by remodeling the TME of PDAC and inducing a long-term, specific antitumor immune response. This evidence concerns the gene IL27 and cancer.